• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Perrigo Company plc filed SEC Form 8-K: Regulation FD Disclosure

    6/4/25 4:54:22 PM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email
    8-K
    PERRIGO Co plc 00-0000000 1 false 0001585364 0001585364 2025-06-02 2025-06-02 0001585364 prgo:OrdinaryShares0001ParValueMember 2025-06-02 2025-06-02 0001585364 prgo:A4.900SeniorNotesDueJune152030Member 2025-06-02 2025-06-02 0001585364 prgo:A6.125SeniorNotesDue2032Member 2025-06-02 2025-06-02 0001585364 prgo:A5.375SeniorNotesDue2032Member 2025-06-02 2025-06-02 0001585364 prgo:A5.30UnsecuredSeniorNotesDueNovember152043Member 2025-06-02 2025-06-02 0001585364 prgo:A49SeniorLoanDue2024Member 2025-06-02 2025-06-02
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):

    June 2, 2025

     

     

    Perrigo Company plc

    (Exact name of registrant as specified in its charter)

     

     

    Commission file number 001-36353

     

    Ireland   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74

    +353 1 7094000

    (Address, including zip code, and telephone number, including

    area code, of registrant’s principal executive offices)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities Registered pursuant to section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Ordinary shares, €0.001 par value   PRGO   New York Stock Exchange
    4.900% Notes due 2030   PRGO30   New York Stock Exchange
    6.125% Notes due 2032   PRGO32A   New York Stock Exchange
    5.375% Notes due 2032   PRGO32B   New York Stock Exchange
    5.300% Notes due 2043   PRGO43   New York Stock Exchange
    4.900% Notes due 2044   PRGO44   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    ITEM 5.02.

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

    On June 2, 2025, Ronald Janish and Perrigo Company plc (“Perrigo” or the “Company”) reached mutual agreement regarding his planned retirement. As agreed, Mr. Janish will step down from his current position as Executive Vice President, Global Operations and Supply Chain of the Company, effective June 23, 2025. Following such date, Mr. Janish will continue in an advisory capacity until September 30, 2025.

    Subject to a general release of claims and other applicable obligations, upon his separation from the Company, Mr. Janish will be entitled to a lump sum severance payment equal to 2.5 times his base salary and target annual bonus and statutory redundancy payments under the Company’s Irish Severance Programme, as well as continued vesting of his equity awards pursuant to his employment agreement. The foregoing summary is qualified in its entirety by reference to Mr. Janish’s compromise waiver agreement, a copy of which is attached hereto as Exhibit 10.1.

     

    ITEM 7.01.

    Regulation FD Disclosure

    On June 4, 2025, Perrigo announced the appointment of Matt Winterman as Executive Vice President of Global Operations and Supply Chain, effective June 23, 2025. Mr. Winterman brings more than 20 years of global supply chain and strategy leadership to Perrigo. Most recently, he served as SVP of Global Supply Chain and Strategy at AstraZeneca, overseeing a $54 billion supply chain across 5,000 SKUs. In this capacity, he was instrumental in driving transformation and strategic investment in the manufacturing network. He also served as Global Head of end-to-end Supply Chain at Roche Holding AG, and in roles of increasing responsibility for technical operations strategy and supply chain performance at GSK plc. Mr. Winterman graduated with a Bachelor of Science degree in Economics from the University of Bristol.

    On June 4, 2025, Perrigo issued a press release announcing Mr. Janish’s retirement and Mr. Winterman’s appointment, a copy of which is attached hereto as Exhibit 99.1. Perrigo undertakes no obligation to update, supplement or amend the press release attached hereto as Exhibit 99.1.

    The information in Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


    ITEM 9.01.

    Financial Statements and Exhibits

     

    (d)

    Exhibits

     

    Exhibit
    Number

      

    Description

    10.1    Compromise Waiver Agreement, dated June 2, 2025, between Perrigo Corporation DAC and Ronald Janish. Certain information in this exhibit has been redacted pursuant to Item 601(a)(6) of Regulation S-K.
    99.1    Press Release issued by Perrigo Company plc on June 4, 2025 furnished solely pursuant to Item 7.01 of Form 8-K.
    104    Cover Page Interactive Data file (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        (Registrant)
        PERRIGO COMPANY PLC
        By:  

    /s/ Eduardo Bezerra

    Dated: June 4, 2025

          Eduardo Bezerra
          Chief Financial Officer
    Get the next $PRGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 13, 2023 - FDA Approves First Nonprescription Daily Oral Contraceptive

      For Immediate Release: July 13, 2023 Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stor

      7/13/23 8:32:15 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care